Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Emiliano Cocco, F. Javier Carmona, Pedram Razavi, Helen H. Won, Yanyan Cai, Valentina Rossi, Carmen Chan, James Cownie, Joanne Soong, Eneda Toska, Sophie G. Shifman, Ivana Sarotto, Peter Savas, Michael J. Wick, Kyriakos P. Papadopoulos, Alyssa Moriarty, Richard E. Cutler, Francesca Avogadri-Connors, Alshad S. Lalani, Richard P. BryceSarat Chandarlapaty, David M. Hyman, David B. Solit, Valentina Boni, Sherene Loi, José Baselga, Michael F. Berger, Filippo Montemurro, Maurizio Scaltriti

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds